glp 1 multiple sclerosis GLP-1 Receptor Agonist Use Associated With Greater Physical Activity and Improved Patient-Reported Outcomes in Ozempic and Multiple Sclerosis: Insights

Censani M, Chin VL, Fennoy I

GLP-1 shares a highly conserved alanine at position 9 with GIP and GLP-2, making these peptides ideal substrates for dipeptidyl peptidase 4 (DPP-4)

Woo YS, Lim HK, Wang SM, Bahk WM

If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns

Products can differ in size, shape, color, and markings from country to country